TWST — Twist Bioscience Corporation

Summary of Twist Bioscience Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $103.7 million, up 17% year-over-year and approximately 5% sequentially.
• Gross Margin: 52%, an increase of 4 percentage points from the previous year, supported by revenue growth and process improvements.
• Adjusted EBITDA: Loss of $13.4 million, an improvement of $2.8 million compared to the prior year.
• Operating Expenses: Increased to $86.9 million from $77.5 million year-over-year, driven by investments in commercial capabilities.
• Cash Position: Ended the quarter with $197.9 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Growth Strategy: The company continues to leverage its semiconductor-based DNA synthesis platform to enhance speed, scale, quality, and affordability, which has resulted in a compound annual growth rate (CAGR) of 24% over the past three years.
• Market Expansion: The serviceable addressable market has grown from $2 billion in 2020 to approximately $7 billion today, with expectations to exceed $12 billion by 2030.
• AI-Enabled Discovery: Significant demand in AI-driven drug discovery is noted, with over $25 million in orders booked in fiscal 2025, indicating a strong customer return for repeat orders.
• Product Innovation: Continued introduction of new products across DNA synthesis and protein solutions, with a focus on AI applications.

3. Forward Guidance and Outlook

• Revenue Guidance: For fiscal 2026, total revenue is expected to be between $435 million and $440 million, reflecting approximately 16% growth at the midpoint.
• Adjusted EBITDA Breakeven: The company remains committed to achieving adjusted EBITDA breakeven by the end of fiscal 2026.
• Growth Expectations: Anticipated strong sequential growth in NGS applications and confidence in existing partnerships, with new partnerships expected to support growth in 2027 and beyond.

4. Bad News, Challenges, or Points of Concern

• Customer Dependency: While a major customer that previously caused revenue fluctuations has returned, the company remains vigilant about potential single-customer dynamics that could impact future revenue.
• Investment Risks: Increased operating expenses due to investments in commercial and digital capabilities may pressure short-term profitability, although these investments are seen as necessary for long-term growth.
• Competitive Landscape: The company acknowledges the need to stay ahead of competitors, particularly in the rapidly evolving AI-driven market, and is focused on maintaining a competitive edge.

5. Notable Q&A Insights

• AI Demand Durability: CEO Emily Leproust expressed confidence that AI-driven demand is not a fleeting trend, citing repeat orders from major customers and an expanding customer base in the pharmaceutical sector.
• Gross Margin Expectations: Management indicated that while gross margins are expected to remain above 52%, improvements will be moderated due to ongoing investments in capacity and automation.
• New Partnerships: The focus for 2026 is on leveraging existing partnerships for growth, with new partnerships anticipated to be crucial for sustained growth in 2027 and beyond.

Overall, Twist Bioscience reported a strong quarter with consistent revenue growth and strategic investments aimed at capitalizing on emerging opportunities, particularly in AI-driven drug discovery, while navigating potential risks associated with customer dependency and competitive pressures.